Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

Inclusion Criteria

• 18 to 40 years of age, inclusive.
• Read, signed, and dated informed consent document.
• Available for follow-up for the planned duration of the study (six months after last immunization).
• Acceptable medical history by screening evaluation and limited physical assessment.
• If the subject is female and of childbearing potential, negative serum or urine pregnancy test at screening and within 24 hours prior to vaccination.
• If the subject is female and of childbearing potential*, she agrees to practice abstinence** or use acceptable contraception*** through 56 days after the last vaccination in order to avoid pregnancy:
• a woman is considered of childbearing potential unless post-menopausal (>/= 1 year without menses) or surgically sterilized (tubal ligation, bilateral oophorectomy, or hysterectomy)

**No sexual intercourse with men (vaginal penetration by a penis, coitus)

***Acceptable contraception methods are restricted to effective devices (IUDs, NuvaRing®) or licensed hormonal products with use of method for a minimum of 30 days prior to vaccination, condoms with spermicidal agents, monogamous relationship with a vasectomized partner who has been vasectomized for 6 months or more prior to study entry, or successful Essure placement with documented confirmation test at least 3 months after the procedure, and any other FDA-approved contraceptive method

• Negative test for HIV.
• Alanine Aminotransferase (ALT) 3,800 and /=120,000/mm^3
• Body mass index >/=18.5- /= 150mmHg or diastolic blood pressure >/= 100mmHg.
• Ten percent or greater risk of developing a myocardial infarction or coronary death within the next 10 years using the National Cholesterol Education Program's (NCEP) risk assessment tool*

*NOTE that this criterion applies only to subjects 20 years of age and older AND only if at least one of the following apply:

• have smoked a cigarette in the past month, and/or
• have hypertension (defined as systolic blood pressure >140 mm Hg) or are on antihypertensive medication, and/or
• have a family history of coronary heart disease in male first-degree relative (father or brother) 5 mg prednisone or equivalent is considered high dose and immunosuppressive
• Corticosteroid nasal sprays for allergic rhinitis are permissible
• Persons who are using a topical steroid for mild uncomplicated dermatitis such as poison ivy or contact dermatitis may be enrolled the day after their therapy is completed
• Inhaled steroids for asthma are not permissible
• Oral/parenteral corticosteroids given for non-chronic conditions not expected to recur are permissible if the length of therapy was </= 14 days with completion at least 30 days prior to enrollment.
• Medical or psychiatric condition or occupational responsibilities that preclude subject compliance with the protocol.
• Any history of illegal injection drug use.
• Receipt or planned receipt of inactivated vaccine from 14 days prior to the first vaccination through 14 days post second vaccination.
• Receipt or planned receipt of any other live attenuated vaccine within 30 days prior to the first vaccination through 30 days post second vaccination.
• Use of any other experimental agent within 30 days prior to vaccination and for the duration of the subject's participation in the study.
• Receipt of blood products or immunoglobulin, including Rhogam, within six months prior to vaccination.
• Donation of a unit of blood within 56 days prior to vaccination or planned donation prior to 28-days following the last vaccination.
• Pregnant or breastfeeding women.
• Active exfoliative skin disorders/conditions, current varicella zoster virus infection, or any acute skin disorders of large magnitude, e.g., laceration requiring sutures, burn greater than 2×2 cm.
• Any condition that, in the opinion of the investigator, might interfere with assessing the study objectives.
• Known allergy to egg, aminoglycoside (including gentamicin) or c